The Week Ahead: COS...
Health Care: Drugs
Vertex Pharmaceuticals (VRTX: NASDAQ)
$78.40 -0.08 | -0.10%
05/24/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -51.14M | 41.18M | -754.63M | -642.18M |
| Operating Gains/Losses | 390.00K | 55.00K | 39.00K | 20.35M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 39.91M | -170.61M | -2.92M | 13.90M |
| (Increase) Decrease in Inventories | -29.92M | -111.39M | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 14.89M | 37.47M | -1.18M | -15.06M |
| (Decrease) Increase In Other Current Liabilities | 17.87M | 125.62M | 6.79M | 7.45M |
| (Increase) Decrease In Other Working Capital | -44.28M | -72.44M | -65.86M | 53.06M |
| Other Non-Cash Items | 257.52M | 249.62M | 138.87M | 99.59M |
| Net Cash From Continuing Operations | 267.84M | 143.74M | -635.44M | -427.59M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 267.84M | 143.74M | -635.44M | -427.59M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 1.37B | 1.02B | 1.28B | 788.26M |
| Purchases of Property, Plant & Equipment | -71.14M | -94.60M | -38.05M | -23.50M |
| Acquisitions | 0.00 | 0.00 | 0.00 | -87.42M |
| Purchases of Short-Term Investments | -1.71B | -721.54M | -1.23B | -1.19B |
| Other Cash from Investing Activities | -16.78M | 12.51M | -4.73M | 624.00K |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -425.82M | 212.41M | 7.30M | -508.73M |
| Issuance of Debt | 0.00 | 0.00 | 391.64M | 149.90M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 191.72M | 124.86M | 33.43M | 849.24M |
| Repayment of Long-Term Debt | -21.49M | -250.00M | -22.00K | -131.00K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 1.97M | 900.00K | 0.00 | 0.00 |
| Net Cash From Financing Activities | 172.20M | -124.24M | 425.06M | 999.01M |
| Effect of Exchange Rate Changes | -141.00K | 214.00K | -377.00K | -5.14M |
| Net Change in Cash & Cash Equivalents | 14.09M | 232.12M | -203.46M | 57.54M |
Portfolios with VRTX
- Portfolio NameUser Type
- UserDC
- UserPortfolio
- ProDaniel Loeb - Third Point
- UserMike Fatah's Mega Stock Por...
- Contributor10 Companies That Prove Sto...
- ContributorRelative Strength Trades fo...
- ContributorEarnings Short Squeeze Play...
- ProD.E. Shaw
- ContributorEarnings Short Squeeze Play...
- Contributor10 Hep C Stocks on Wall Str...
Latest VRTX Headlines from TheStreet
- Worth Repeating: Vertex Is the Next Gilead Sciences 04.19.13 | 08:04 am
- Futures Point Higher; Boston Manhunt Plays Out
04.19.13 | 08:04 am - The New #38 Most Shorted Nasdaq 100 Component: Vertex Pharmaceuticals 04.10.13 | 04:04 pm
- Analysts' Actions: JNJ FNFG WLL CA VRTX 04.08.13 | 08:04 am
- Cramer's Top Stock Picks: WM VRTX SRPT NPSP DR 04.03.13 | 06:04 am
- Cramer's 'Mad Money' Recap: The Winning Formula 04.02.13 | 08:04 pm
- Most Profitable Second Quarter Biotech Stocks 04.02.13 | 06:04 am
- 3 Stocks Pushing The Drugs Industry Higher 03.08.13 | 12:03 pm
- Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Winner 03.06.13 | 05:03 pm
- Vertex Pharmaceuticals Stock Sell Recommendation Reiterated (VRTX) 03.04.13 | 09:03 am
Press Releases for VRTX
- VX-787 Showed Significant Antiviral Activity And Reduced The Severity And Duration Of Influenza Symptoms In Phase 2 Challenge Study - Business Wire 03.04.13 | 08:03 am
- Vertex Announces Webcasts Of Its Presentations At Two Investor Conferences - Business Wire 02.27.13 | 04:02 pm
- Vertex Announces Initiation Of Pivotal Phase 3 Program Of VX-809 In Combination With Ivacaftor For The Treatment Of People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation - Business Wire 02.26.13 | 04:02 pm
- Republic Of Ireland Approves Funding For KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis, For People With A Specific Genetic Mutation (G551D) - Business Wire 02.01.13 | 12:02 pm
- Vertex Reports Full-Year And Fourth Quarter 2012 Financial Results And Provides Updates On Key Development Programs - Business Wire 01.29.13 | 04:01 pm
- Vertex To Report Fourth Quarter And Full Year 2012 Financial Results On Tuesday, January 29 - Business Wire 01.15.13 | 04:01 pm
- Vertex Outlines Corporate Strategy And Defines Key 2013 Business Priorities - Business Wire 01.06.13 | 05:01 pm
- NHS In England Funds KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis, For People With A Specific Genetic Mutation (G551D) - Business Wire 12.19.12 | 09:12 am
- Vertex Announces Update To U.S. Prescribing Information For INCIVEK® (telaprevir) - Business Wire 12.19.12 | 08:12 am
- Health Canada Approves KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People With A Specific Genetic Mutation (G551D) - Business Wire 12.03.12 | 08:12 am
Partner Headlines for VRTX
- Market Close Report: NASDAQ Composite index closes at 3,206.06 up 39.70 points - NASDAQ 04.19.13 | 08:04 pm
- Stocks Up, Dow Turns Positive; Leaders Catch An Updraft - Investor's Business Daily 04.19.13 | 12:04 pm
- UPDATE: Credit Suisse Raises PT on Vertex Pharmaceuticals on Cystic Fibrosis Franchise De-Risking - Benzinga 04.19.13 | 09:04 am
- Futures Geared For Higher Open; Vertex, Google, Chipotle Rumble - Investor's Business Daily 04.19.13 | 08:04 am
- Stocks Take Another Drubbing, But Google Rises After Hours - Investor's Business Daily 04.18.13 | 05:04 pm
- Regeneron Pharmaceuticals Inc (REGN): Today's Most Compelling Buy - NASDAQ 03.14.13 | 04:03 pm
- Market Close Report: NASDAQ Composite index closes at 3,244.37 up 12.28 points - NASDAQ 03.08.13 | 09:03 pm
- Gilead Stock Hits New High As HCV Drug Keeps Rocking - Investor's Business Daily 02.19.13 | 04:02 pm
- RIM, Green Mountain and Other Top Performing Nasdaq Stocks in November - Benzinga 12.01.12 | 01:12 pm
- Celgene, Regeneron Pharmaceutical Lead Biomed Group - Investor's Business Daily 11.30.12 | 05:11 pm
